Regenerative Biology – Regbiomed http://regbiomed.com/ Fri, 14 Jan 2022 12:35:10 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://regbiomed.com/wp-content/uploads/2021/09/icon-150x150.png Regenerative Biology – Regbiomed http://regbiomed.com/ 32 32 Maldives Underwater Initiative at Six Senses Laamu Recognized for Conservation with Global Award https://regbiomed.com/maldives-underwater-initiative-at-six-senses-laamu-recognized-for-conservation-with-global-award/ Fri, 14 Jan 2022 07:42:05 +0000 https://regbiomed.com/maldives-underwater-initiative-at-six-senses-laamu-recognized-for-conservation-with-global-award/ The MUI team with Marteyne van Well, General Manager of Six Senses Laamu. A green sea turtle spotted near L. Gaadhoo. It is the most important nesting site for green turtles in the Maldives and is now a marine protected area. The MUI team is on an excursion with a local school through the L. […]]]>

The MUI team with Marteyne van Well, General Manager of Six Senses Laamu.

A green sea turtle spotted near L. Gaadhoo. It is the most important nesting site for green turtles in the Maldives and is now a marine protected area.

The MUI team is on an excursion with a local school through the L. Hithadhoo mangrove, which has also been declared a marine protected area.

The announcement comes just two months after the atoll was declared a Hope Spot by Mission Blue.

LAAMU, MALDIVES – The Maldives Underwater Initiative (MUI) was recently recognized as a world leader in marine conservation during the 20th Skål International Award for Sustainable Tourism. Shortly thereafter, the Maldivian President Ibrahim Mohamed Solih and its administration has designated six naturally unique and ecologically resource-rich areas in Laamu Atoll as Marine Protected Areas (MPAs). The announcement comes just two months after the atoll was declared a Hope Spot by Mission Blue.

Recognition of progress in conservation
MUI, the Six Senses Laamu marine biology team, made up of guests from the resort and its three partner NGOs: The Manta Trust, Blue Marine Foundation and The Olive Ridley Project, was named the marine and coastal category winner at the 2021 Skål International Sustainable Tourism Awards. This is the second Skål trophy presented at Six Senses Laamu after the resort was crowned winner of the same category in 2018. Three experts Sustainability Independents judged 50 entries from 26 countries, placing MUI at the top of its category ahead of five other projects.

Receiving this award twice is an incredible achievement“, Explain Marteyne van Well, General Manager of Six Senses Laamu, “and it’s a testament to the progress MUI has made in marine conservation since we won our first Skål award three years ago.

This award celebrates the team’s dedication to marine conservation through their work in research, education and community outreach. Their research has been presented at both scientific symposia and government meetings to drive policy change. They provided 199 Laamu children with marine conservation and environmental education and took 566 students from local schools on snorkeling trips. Since 2019, they have had 26,000 educational moments with guests and certified 165 children in their junior marine biology program.

Six designated marine protected areas
Just a day after the award was announced, MUI celebrations continued when the President of the Maldives, Mr. Ibrahim Mohamed Solih, announced that six MPAs would come to Laamu. The team has been working on this step for many years.

Since MUI’s inception, our ultimate goal has been to protect Laamu’s marine habitats and key megafauna species through legislation.,” said Philippa Roe, Chief Marine Biologist of the MUI. “For years, the partners within MUI – Six Senses Laamu, the Manta Trust, Blue Marine Foundation and the Olive Ridley Project – have collected research on Laamu’s marine ecosystems and species, much of which has been used as evidence to support marine protection..”

Areas that have been designated for marine protection include the turtle nesting beach, the mangrove and seagrass area of ​​L. Gaadhoo (an uninhabited island neighboring Six Senses Laamu), the channel between Six Senses Laamu and L. Gaadhoo, L. Hithadhoo Mangrove (an inhabited island on the other side of Six Senses Laamu), as well as two channels, a mangrove, a wetland and an island in other areas of the atoll.

The new MPAs, comprised of interconnected coral reefs, mangroves and seagrass beds, will support the Laamu community by protecting fish populations and livelihoods while maintaining climate-resilient reefs“, Explain Shaha Hashim, the Maldives project manager for Blue Marine Foundation and a driving force behind the designation of MPAs.

Welcome to Regenerative Travel Activism
The Skål award wasn’t the only award received at Laamu last month. On December 15, 2021, the winners of the Regenerative Travel 2021 Impact Awards were announced and Shaha was recognized as the Regenerative Activist of the Year. The award recognizes her dedication to these MPA designations by describing her as “a voice for many who do not have the capacity or the platform to speak, working towards equitable and well-managed resources based on scientific evidence.”

Now that these MPAs have been designated, the Ministry of Environment will work with stakeholders, including atoll and island councils, to develop management plans for each area. MUI and the Blue Marine Foundation will continue to work with local community members and leaders on the atoll, providing advice and assistance where needed.

Mission Blue Hope Spot
This good news comes just two months after Laamu Atoll was declared a Hope Spot by the international non-profit marine conservation organization Mission Blue. The Hope Spot announcement highlighted the importance of marine ecosystems in the atoll and the need for additional protection.

]]>
GHO Capital invests in CDMO RoslinCT cell therapy https://regbiomed.com/gho-capital-invests-in-cdmo-roslinct-cell-therapy/ Wed, 12 Jan 2022 15:46:48 +0000 https://regbiomed.com/gho-capital-invests-in-cdmo-roslinct-cell-therapy/ Global healthcare opportunities, or GHO Capital Partners LLP, a specialist European investor, has invested in RoslinCT, a contract development and manufacturing organization ( CDMO ) focused on advanced cell therapies. Founded in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was established through an initial spin-off from the Roslin Institute, which has a […]]]>
Global healthcare opportunities, or GHO Capital Partners LLP, a specialist European investor, has invested in RoslinCT, a contract development and manufacturing organization ( CDMO ) focused on advanced cell therapies.

Founded in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was established through an initial spin-off from the Roslin Institute, which has a proven track record in genetic and cellular biology.

Since 2014, the company has had a manufacturing base within the Center for Regenerative Medicine at the University of Edinburgh in a facility shared with the Scottish National Blood Transfusion Service. RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high quality cell therapy development and manufacturing. The company recently expanded into the facilities of the Edinburgh BioQuarter and is recognized worldwide as a unique CDMO establishing its own production on a commercial scale.

RoslinCT serves an established international customer base of leading pharmaceutical and biotechnology companies, in partnership from the development phase through to advanced clinical manufacturing. The company is expected to experience exponential growth in the advanced therapy market, which is expected to grow by up to 50% per year.

With the support of GHO, RoslinCT will significantly increase its development and manufacturing capacity, supporting customer acquisition and product diversification.

RoslinCT will benefit from GHO’s industry expertise and international resources to accelerate its growth, evolve the business to build on its best-in-class therapies and better serve a growing international clientele.

GHO Capital partners commented, “RoslinCT is renowned for its world-class services in the development and manufacture of advanced cell therapies and we are delighted to join the team. With an established track record in regenerative medicines and a strong foothold in Scotland as a leading center for cell therapy research, RoslinCT, with our investments and specialist expertise, is uniquely positioned to drive the next stage of its growth. We look forward to realizing RoslinCT’s shared ambition to become a global CDMO with commercialized cell therapy manufacturing capabilities. “

Janet Downie of RoslinCT said: “After building RoslinCT and our highly skilled team over many years, I am delighted to have the support of GHO. GHO has extensive healthcare expertise which is essential as we seek to drive global growth and expand our operations to meet growing international demand. With tremendous advancements in the cell therapy industry, RoslinCT is now perfectly positioned to become a truly global CDMO, having grown in strength in recent years. I see this as a very natural and exciting step for the business and we look forward to taking further steps with the support of GHO.

Malcolm Bateman, CEO of The Roslin Foundation, added: “I am delighted to recognize the success of the company that I, along with my colleagues at the Roslin Institute, established in 2006. The Roslin Foundation has enjoyed working with it. excellent RoslinCT team over the years. This is a fantastic achievement and we are confident that the company, in partnership with GHO, will continue to set the standard for manufacturing high quality cell therapy. We wish everyone involved the best for the future.

Slaughter & May acted as legal advisor to GHO, and Alvarez and Marsal acted as both financial and tax advisor, Deloitte as structuring advisor, ClearView Healthcare Partners as business advisor, Dark Horse Consulting Group as technical advisor and ERM as ESG advisor.

Torreya Partners (Europe) LLP served as financial advisor to RoslinCT and Dentons provided legal advice.

]]>
Global Regeneration Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type and End Use – Industrial Computing https://regbiomed.com/global-regeneration-market-status-2016-2020-and-forecast-2021e-2026f-by-region-product-type-and-end-use-industrial-computing/ Sat, 08 Jan 2022 17:02:22 +0000 https://regbiomed.com/global-regeneration-market-status-2016-2020-and-forecast-2021e-2026f-by-region-product-type-and-end-use-industrial-computing/ Global regeneration market research is an intelligence report with meticulous efforts undertaken to study accurate and valuable information. The data that has been examined is calculated taking into account both the best existing players and future competitors. The business strategies of major players and new industries entering the market are studied in detail. A well […]]]>

Global regeneration market research is an intelligence report with meticulous efforts undertaken to study accurate and valuable information. The data that has been examined is calculated taking into account both the best existing players and future competitors. The business strategies of major players and new industries entering the market are studied in detail. A well explained SWOT analysis, revenue share and contact details are shared in this report analysis. It also provides information on the market in terms of development and its capabilities.

Request a sample copy of this report (use company email id for higher priority) @ https://www.mraccuracyreports.com/report-sample/498909

Summary

Regenerative Medicine is a branch of translational research in tissue engineering and molecular biology that deals with the process of replacing, engineering, or regenerating human cells, tissues or organs to restore or establish normal function. This is through the use of innovative medical means to rebuild diseased or damaged tissue or to support the regeneration of diseased or damaged tissue. The methods used include cell therapy, tissue engineering, chemically and therapeutically induced cloning, etc. Any combination of these technologies can be used to harness or stimulate the body’s innate healing ability to treat a wide range of illnesses, including musculoskeletal conditions. , cardiovascular and peripheral vascular diseases, neurological disorders, strokes, non-healing wounds and eye diseases

The report predicts that the global regeneration market is expected to grow to reach USD xxx million in 2020 with a CAGR of xx% during the period 2021E-2026F due to the coronavirus situation.

The report offers detailed coverage of the Regeneration industry and key market trends with impact of Coronavirus. The market research includes historical and forecast market data, demand, application details, price trends and company shares of the major Regenerators by geography. The report divides the market size, by volume and value, based on application type and geography.

First of all, this report covers the current status and the future prospects of the global regeneration market for 2016-2025.

And in this report, we analyze the global market of 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East and Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

At the same time, we classify Regenerative by type, application by geography. More importantly, the report includes the major countries market on the basis of type and application.

Finally, the report provides detailed profile analysis and data insights of leading Regeneration Company.

Key content of the chapters as follows (including and can be customized):

Part 1:

Market Overview, Development, and Segment by Type, Application, and Region

Part 2:

Company information, sales, cost, margin, etc.

Part 3:

Global Market by Company, Type, Application, and Geography

Part 4:

Asia-Pacific Market by Type, Application, and Geography

Part 5:

European market by type, application and geography

Part 6:

North America Market by Type, Application, and Geography

Part 7:

South America Market by Type, Application, and Geography

Part 8:

Middle East & Africa Market by Type, Application, and Geography

Part 9:

Market characteristics

Part 10:

Investment opportunity

Part 11:

Conclusion

Market segment as follows:

By region

Asia Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East and Africa[GCC, North Africa, South Africa]

South America[Brazil, Argentina, Columbia, Chile, Peru]

Key companies

CPKelco

Ingredients Parmalat Canada

Calpro Foods

Market by type

Microparticulate protein

Modified whey protein concentrate

Others

Market by application

Dairy products

Meat products

Others

Get Up To 30% Off On First Purchase Of This Report @: https://www.mraccuracyreports.com/check-discount/498909

The key questions the report answers:

  • What will the market size and growth rate be by the end of the forecast period?
  • What are the key trends in the global regeneration market impacting the market growth?
  • What are the potential growth opportunities and threats faced by the major competitors in the market?
  • What are the key findings of Porter’s five forces analysis and SWOT analysis of major players operating in the global regeneration market?
  • This report gives all the information regarding the industry overview, analysis, and revenue for this market.
  • What are the market opportunities and threats faced by the vendors in the global Regeneration Market?

If you have any special requirement, please let us know and we will offer you the report you want.

Buy Now @ https://www.mraccuracyreports.com/checkout/498909

About Us:

RM Precision Reports provides customization of reports according to your needs. This report can be customized to meet your needs. Contact our sales team, who will ensure you get a report tailored to your needs.

Contact us:

      Call: +1 804 500 1224 / +44 741841 3666 (International)

E-mail: [email protected]

Website: www.mraccuracyreports.com


Source link

]]>
Four new collaborations to move the world of drug R&D https://regbiomed.com/four-new-collaborations-to-move-the-world-of-drug-rd/ Thu, 06 Jan 2022 18:49:24 +0000 https://regbiomed.com/four-new-collaborations-to-move-the-world-of-drug-rd/ Collaborations are part of the lifeblood of the pharmaceutical industry. At the start of 2022, several companies have partnerships already announced which will advance the potential of new drugs in various disease indications. And this trend continues today with more collaborative agreements. Alnylam and Novartis join forces Two industry giants, Alnylam Pharmaceuticals and Novartis have […]]]>

Collaborations are part of the lifeblood of the pharmaceutical industry. At the start of 2022, several companies have partnerships already announced which will advance the potential of new drugs in various disease indications. And this trend continues today with more collaborative agreements.

Alnylam and Novartis join forces

Two industry giants, Alnylam Pharmaceuticals and Novartis have twinned in an RNA pact. The companies aim to take advantage of Alnylam’s siRNA technology in the treatment of liver disease. The collaboration will use siRNA to inhibit a target discovered by Novartis, which could lead to the regrowth of functioning liver cells. And it could provide an alternative to liver transplants in patients with organ failure.

Currently, a liver transplant is the only treatment for end-stage liver failure. There is a significant need for medicinal alternatives to transplants that “regenerate liver tissue and restore essential metabolic and synthetic processes that are handled by the liver,” the companies said.

As part of the three-year research collaboration, Alnylam will develop and test potential siRNAs that use target-specific assays developed by the Swiss pharmaceutical giants. Novartis will take over development and clinical research when a lead candidate is identified.

Jay Bradner, president of the Novartis Institutes for Biomedical Research, said the partnership with Alnylam builds on a “legacy of leadership in regenerative medicine”. With siRNA technology, the goal is to bring a transformative benefit to patients with hepatic impairment.

2seventy and Novo Nordisk join forces in gene therapy

270 organic and Novo Nordisk entered a license agreement for the development of an in vivo gene editing treatment for hemophilia A. Novo Nordisk has the option to license the megaTAL technology based on the proprietary mRNA of 2seventy bio. They intend to exploit the megaTAL technology to develop a new approach for patients with hemophilia A. The aim is to create a treatment that offers a sustained therapeutic effect.

2seventy bio’s megaTAL technology has the potential to provide a very specific and effective means of “silencing, modifying or inserting genetic components”. Hemophilia A is a genetic bleeding disorder that results from defective factor VIII.

The partnership between the two companies builds on previous hemophilia research conducted by Novo Nordisk and bluebird bio.

Under the terms of the agreement, 2seventy bio will receive an upfront payment of $ 5 million. The company is also eligible for milestone payments as well as a net sales royalty. Novo Nordisk will be responsible for funding all research and development activities.

Sosei and Verily team up to develop drug candidates against GPCR targets

from Japan Sosei group company and the alphabet In truth forged a strategic collaboration for advance understanding of the biology of GPCRs in immune cells and develop therapies against these targets. The agreement combines the complementary capabilities of Verily’s immune profiling and the structure-based drug design of Sosei Heptares G-Protein Coupled Receptors (GPCRs).

The two companies intend to better understand the biology of GPCRs for uses in immunology, gastroenterology, immuno-oncology and other disorders with immunoprotective or immunopathogenic mechanisms. Through the use of Sosei’s StaR (stabilized receptor) platform, the companies aim to create flagship molecules for further development or licensing.

Financial terms of the collaboration were not disclosed.

Janssen and TRexBio partner on immune-mediated disease

Janssen Pharmaceuticals, a Janssen company, and TRexBio, Inc. have forged a multi-year research and licensing collaboration for the discovery of novel tissue-targeted therapies that harness the capabilities of TRexBio’s proprietary deep biology platform.

Currently, TRexBio uses its platform to generate information on the immune regulation of human tissues. From there, the company can identify new therapeutic targets by focusing on modulating the regulatory T cell (Treg) response. Both companies will use the TRexBio platform to discover new targets to address unmet needs in immune-mediated diseases. Janssen will be responsible for the clinical development and commercialization of therapeutic products resulting from the collaboration.

Details of financial terms were not disclosed. TRex said Janssen will provide the company with upfront payment, option fees, milestones and royalties.


Source link

]]>
Humacyte Announces Appointment of Three Surgical and Cardiovascular Opinion Leaders to Advisory Positions https://regbiomed.com/humacyte-announces-appointment-of-three-surgical-and-cardiovascular-opinion-leaders-to-advisory-positions/ Sat, 01 Jan 2022 00:46:50 +0000 https://regbiomed.com/humacyte-announces-appointment-of-three-surgical-and-cardiovascular-opinion-leaders-to-advisory-positions/ DURHAM, NC, December 31, 2021 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues on a commercial scale, announced today the appointment of Surgical Key Opinion Leaders (KOL) Alan P. Kypson, MD, FACS; Luigi Pascarella, MD, FACS; and Todd E. Rasmussen, MD, FACS, (Col, ret. USAF […]]]>

DURHAM, NC, December 31, 2021 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues on a commercial scale, announced today the appointment of Surgical Key Opinion Leaders (KOL) Alan P. Kypson, MD, FACS; Luigi Pascarella, MD, FACS; and Todd E. Rasmussen, MD, FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, KOLs will bring their expertise and support to guide human acellular vessel training and clinical advancement efforts.MT (HAV) and help identify opportunities to advance the complex tissue constructs pipeline and platform at an early stage of the company.

Humacyte HAVs are ready-to-use replacement vessels currently being evaluated in advanced clinical trials in the areas of vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease (PAD). HAVs are also being used to treat patients with severe PAD under investigator-sponsored IND No. 27864, filed with the United States Food and Drug Administration (FDA) by Dr. Rasmussen, at the Mayo Clinic in Rochester, Minn.

“Dr. Kypson, Pascarella and Rasmussen are luminaries in the fields of cardiac, vascular and traumatic surgery, and we have had the pleasure of working with them in a variety of capacities as we developed HAV,” said Laura Niklason, MD , Ph.D., Founder, President and CEO of Humacyte. “We are delighted to now formalize their roles as foundational advisors to our clinical and surgical teams, as we prepare for our next phase of growth, the anticipated commercialization of HAV in its initial vascular indications and the expected expansion of applications for our off-standard regenerative medicine technology.

Dr Kypson is a cardiothoracic surgeon at Rex Hospital, University of North Carolina, Raleigh, North Carolina. Previously, he was Professor of Surgery at the Brody School of Medicine and Head of the Division of Cardiothoracic Surgery at the East Carolina Heart Institute. Dr Kypson has led the large animal preclinical development of Humacyte vessels in coronary artery bypass grafting for over a decade and has authored over 100 publications, primarily in the area of ​​coronary artery bypass grafting. cardiovascular surgery.

Dr Pascarella is a vascular surgeon and associate professor and vice president of surgery at the University of North Carolina School of Medicine in Chapel Hill, North Carolina. Dr Pascarella received a Fellowship in Vascular Biology in the Department of Bioengineering at the University of California at San Diego and his postgraduate surgical training at Duke University. He has performed preclinical studies on several animal models of vascular disease, including studies with HAV. Dr Pascarella is the author of numerous publications in peer-reviewed medical journals, with an emphasis on vascular surgery, aortic disease and medical education.

Dr Rasmussen is Professor and Vice President of Education in the Department of Surgery and Senior Associate Consultant in the Division of Vascular and Endovascular Surgery at the Mayo Clinic. Prior to joining Mayo, Dr. Rasmussen served nearly three decades in the US Air Force, retiring as Colonel in 2021. While in the Air Force, Dr. Rasmussen completed several periods of service with the Air Force. Middle East and launched a research and innovation program on the control of vascular lesions and hemorrhages. Dr. Rasmussen’s research has resulted in more than 300 publications, primarily in the areas of vascular injury and shock, including two textbooks, the Manual of patient care in vascular disease and Rich’s vascular trauma. He is also the co-inventor of the REBOA Rescue Device, a minimally invasive technique for managing severe bleeding and shock.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve patient lives and transform the practice of medicine. The Company develops and manufactures acellular tissue to treat a wide variety of illnesses, injuries and chronic illnesses. The initial opportunity for Humacyte, a human acellular vessel (HAV) portfolio, is currently in advanced clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric cardiac surgery, the treatment of type 1 diabetes, and multiple new cellular and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Advanced Regenerative Therapy (RMAT) Accelerated Review Designation and received Priority Designation for the Treatment of Vascular Trauma by the US Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
investors@humacyte.com

Humacyte media contact:
media@humacyte.com

Main logo


Source link

]]>
Humacyte announces the appointments of three surgeons and https://regbiomed.com/humacyte-announces-the-appointments-of-three-surgeons-and/ Fri, 31 Dec 2021 12:30:00 +0000 https://regbiomed.com/humacyte-announces-the-appointments-of-three-surgeons-and/ DURHAM, NC, December 31, 2021 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing bioengineered human tissues that are universally implantable at scale Commercial, today announced the appointment of Surgical Key Opinion Executives (KOL) Alan P. Kypson, MD, FACS; Luigi Pascarella, MD, FACS; and Todd E. Rasmussen, MD, FACS, (Col, ret. […]]]>

DURHAM, NC, December 31, 2021 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing bioengineered human tissues that are universally implantable at scale Commercial, today announced the appointment of Surgical Key Opinion Executives (KOL) Alan P. Kypson, MD, FACS; Luigi Pascarella, MD, FACS; and Todd E. Rasmussen, MD, FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, KOLs will provide expertise and support to guide human acellular vessel training and clinical advancement efforts.MT (HAV) and help identify opportunities to advance the complex tissue constructs pipeline and platform at an early stage of the company.

Humacyte HAVs are ready-to-use replacement vessels currently being evaluated in advanced clinical trials in the areas of vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease (PAD). HAVs are also being used to treat patients with severe PAD under investigator-sponsored IND No. 27864, filed with the United States Food and Drug Administration (FDA) by Dr. Rasmussen, at the Mayo Clinic in Rochester, Minn.

“Dr. Kypson, Pascarella and Rasmussen are leaders in the fields of cardiac, vascular and traumatic surgery, and we have had the pleasure of working with them in a variety of capacities as we developed VHA,” said Laura Niklason, MD , Ph.D., Founder, President and CEO of Humacyte. “We are delighted to now formalize their roles as foundational advisors to our clinical and surgical teams, as we prepare for our next phase of growth, the anticipated commercialization of HAV in its initial vascular indications and the expected expansion of applications for our off-standard regenerative medicine technology.

Dr Kypson is a cardiothoracic surgeon at Rex Hospital, University of North Carolina, Raleigh, North Carolina. Previously, he was Professor of Surgery at the Brody School of Medicine and Head of the Division of Cardiothoracic Surgery at the East Carolina Heart Institute. Dr Kypson has led the large animal preclinical development of Humacyte vessels in coronary artery bypass grafting for over a decade and has authored over 100 publications, primarily in the area of ​​coronary artery bypass grafting. cardiovascular surgery.

Dr Pascarella is a vascular surgeon and associate professor and vice president of surgery at the University of North Carolina School of Medicine in Chapel Hill, North Carolina. Diego and his postgraduate surgical training at Duke University. He has performed preclinical studies on several animal models of vascular disease, including studies with HAV. Dr Pascarella is the author of numerous publications in peer-reviewed medical journals, with an emphasis on vascular surgery, aortic disease and medical education.

Dr Rasmussen is Professor and Vice President of Education in the Department of Surgery and Senior Associate Consultant in the Division of Vascular and Endovascular Surgery at the Mayo Clinic. Prior to joining Mayo, Dr. Rasmussen served nearly three decades in the US Air Force, retiring as Colonel in 2021. While in the Air Force, Dr. Rasmussen completed several periods of service with the Air Force. Middle East and launched a research and innovation program on the control of vascular lesions and hemorrhages. Dr. Rasmussen’s research has resulted in more than 300 publications, primarily in the areas of vascular injury and shock, including two textbooks, the Manual of patient care in vascular disease and Rich’s vascular trauma. He is also the co-inventor of the REBOA Rescue Device, a minimally invasive technique for managing severe bleeding and shock.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve patient lives and transform the practice of medicine. The Company develops and manufactures acellular tissue to treat a wide variety of illnesses, injuries and chronic illnesses. The initial opportunity for Humacyte, a human acellular vessel (HAV) portfolio, is currently in advanced clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric cardiac surgery, the treatment of type 1 diabetes, and multiple new cellular and tissue applications. Humacyte’s HAVs were the first product to receive the accelerated review designation of Advanced Regenerative Therapy in Regenerative Medicine (RMAT) from the FDA and received priority designation for the treatment of vascular trauma by the US Secretary of State for Health. Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
investors@humacyte.com

Humacyte media contact:
media@humacyte.com


Source link

]]>
Regenerative approach to agronomy restored a dying enclosure | Earth https://regbiomed.com/regenerative-approach-to-agronomy-restored-a-dying-enclosure-earth/ Mon, 27 Dec 2021 05:00:00 +0000 https://regbiomed.com/regenerative-approach-to-agronomy-restored-a-dying-enclosure-earth/ Regenerative farmer and Farm Mojo consultant Geoff Bassett recently received the Dick Walker Landcare Memorial Award for his contribution to Landcare, agriculture and his community, which includes over 40 years of farming and 20 years of counseling from other farmers in northern New South Wales. One customer is Annabelle Butler from Woombi Station on Tingha […]]]>

Regenerative farmer and Farm Mojo consultant Geoff Bassett recently received the Dick Walker Landcare Memorial Award for his contribution to Landcare, agriculture and his community, which includes over 40 years of farming and 20 years of counseling from other farmers in northern New South Wales.

One customer is Annabelle Butler from Woombi Station on Tingha Road, west of Ben Lomond, where dormant improved pastures have returned to high production without the need for replanting. This increased production costs efficiently without any loss of grazing time. Small but correct inputs, applied at the right time, have reduced this permanent pasture from early disappearance to a fraction of the cost of replanting again.

“A lot of farmers are having problems with low persistence in their permanent pastures,” Mr. Bassett said. “They should last for decades, but many are reseeded after less than five years and it comes at a high cost. In the days of the previous cattle market, producers barely paid back their investment in pasture establishment.

“On Woombi, it started with an application of liquid NPK, trace elements and a microbial product. This produced rapid pasture growth, deeper root systems, and more legume growth. Ideally, we want to strengthen natural processes, not replace them. “

However, Mr. Bassett warns that overuse of soluble nutrients can cause soil health problems because it can interfere with natural soil processes. Healthy grazing nurtures soil biology by exchanging root exudates for soil minerals, in a fragile arrangement with fungi, which easily breaks when a plant receives too much of what it needs in a soluble form.

Soil tests are important tools, but farmers can start looking for themselves and watching for signs the system is working – like monitoring leaves for nitrogen, phosphorus and potassium deficiencies.

“It has long been proven that healthy grass can get 100% of its N requirement from the nitrogen-fixing bacteria that live around the roots of the grass and feed on root exudates,” Bassett said.

“A tip of a green leaf is an indication of an adequate amount of nitrogen for pasture while a tip of a dead leaf is a sign of deficiency.

“We think it should be easier to manage a monoculture, but it creates so many problems with soil health and weeds, that over time you end up with more and more problems.

“With a regenerative approach, you can end up with a self-sustaining system. Healthy plants feed many microbes, which in turn feed the plants with minerals from the soil and increase the humus and air in the soil. This leads to softer soil which has more precipitation infiltration and stores precipitation longer. This is a recipe for a high efficiency, low input system. “

Fresh grass juice squeezed on a refractometer will show the health of pasture.

Reading the signs of nature in the pastures

Weeds are excellent bioindicators and are essentially soil amendments. We need to understand what they are doing and why they are there. We can then address the real causes of pasture decline.

For example, blooming white daisies right now at higher elevations may be a sign that calcium is not available due to a lack of fungus and air in the soil.

Thistles and lush weeds often mean there is an excess of soluble nutrients and can be a sign of an imbalance between calcium and nitrogen, ”says Bassett.

Farmer friends, or cobbler’s ankles, are a sign of excess nutrients. It is a better option for farmers to help the grasses take up these extra nutrients rather than growing those weeds.

Plaintain is an herb, not a weed, although it may seem out of place, it is pest control, high in zinc and copper, and is a good blood clotting agent for humans. It is an essential plant for grazing.

Daikon or tillage radish will do what thistles do well – break up hard soil, feed soil biology, and let in rain and air.

“Nature is incredibly smart at putting plants in the right places. We have to learn from that,” Mr. Bassett said.

Further reading:

Stench burst!

Young Eastern Cattle Index continues to rise

Spray drift course featured this year

Have you signed up for The Land’s free daily newsletter? Sign up below to make sure you are up to date with everything important to New South Wales farming.


Source link

]]>
Crazy Christmas food from the future might be closer than you think https://regbiomed.com/crazy-christmas-food-from-the-future-might-be-closer-than-you-think/ Fri, 24 Dec 2021 22:00:00 +0000 https://regbiomed.com/crazy-christmas-food-from-the-future-might-be-closer-than-you-think/ Laboratory-grown ham with a side of 3D printed vegetables, washed down with a glass of non-alcoholic alcohol. This could be the future of Christmas lunches to come. Key points: From lab-grown meat to ancient grains – Christmas culinary trends stretch over time Technology literally shapes food via 3D printed vegetables Regenerative and Farm Foods Delivered […]]]>

Laboratory-grown ham with a side of 3D printed vegetables, washed down with a glass of non-alcoholic alcohol. This could be the future of Christmas lunches to come.

Only, it is not decades, if not years, these foods are available now, as consumption trends continue to be influenced by changing technologies.

Food futurist Tony Hunter says everything from alternative proteins to cell farming and synthetic biology is changing the food landscape.

Mr Hunter says it is difficult to predict food trends, making it difficult for farmers to respond.

But he assures primary producers that they have more power than they realize when it comes to the future of food.

“No matter what technology we use, we’re going to need farmers to produce these raw materials in order to produce the food stocks to make the food, whatever the technology, so that’s the bottom line, it all comes down to farmers in the end, ”Hunter said.

“I think technology provides opportunities for consumers; consumers choose the opportunities they want and then adopt… technology that meets an unknown need that they have, then it comes back to technologies again and it becomes a circle. “

Mr Hunter says if he brushes his crystal ball he can see cultured meat like steak, lobster and shrimp on the Christmas table in 2030.

3D printed plant-based steak may soon be an option for Christmas dinner(Provided: Redefining Meat)

The alcohol-free drink

One of the biggest growing trends in food and drink circles is the rise of non-alcoholic drinks.

In the heart of Western Australia’s wine country, Margaret River-based distiller Tom Streitberg is celebrating his first year of business as the state’s only non-alcoholic spirits producer.

It was a market he and his business partners – sommelier Christopher Bothwell and winemaker Elizabeth Reed – saw as an opportunity to explore, as consumers began to seek healthier choices.

“The culture of drinking in Australia is changing,” Streitberg said.

“The idea of ​​you going out and having a huge session, you slam a bunch of drinks; that really changes,” Mr. Streitberg said.

He said that with the health crowd, target consumers included pregnant women, people with young children, designated drivers and those who choose not to drink alcoholic beverages.

“It’s not about saying don’t drink at all,” he said.

“So we don’t really see any limits in the market, or the sky is the limit. “

Man in a distillery measuring ingredients
Margaret River based distiller Tom Streitberg(Provided: Paris Hawken Photography)

Ancient grains for the future

Some future food trends are as far removed from modern technology as you can imagine.

Black barley is an ancient cereal from Ethiopia with a vegetable protein composition of 19%.

Roger Duggan started growing black barley five years ago from a sample of seeds small enough to fit in and wrap around.

This year, it will produce up to a hundred tonnes for the home and restaurant market.

He expects ancient grains as well as regenerative and organic farming practices to become more important in future food production.

“Soil health is essential; much of the Asian market is asking for things like testing for glyphosate residues, ”Duggan said.

“They want to hear a story that we really care for the land we live on.”

Black barley in a bag.
Black barley is an ancient cereal from Ethiopia that is high in protein.

Buzzing protein food source

As you walked down the meat aisle at the supermarket looking for your Chrissie lunch, you may have seen the terms grass-fed or grain-fed, but what about fly-fed?

Things like barramundi or fly-fed chicken might be something you will see more of in the future and it’s something that Lauren Bell of Northwest WA has been at the forefront with her flies. black soldiers.

“It’s about creating a more sustainable protein that can be used by the animal industry,” she said.

“So I think there will definitely be a shift towards using a lot more insect protein in poultry feed to make it more sustainable.

Hermetia illucens larvae
Could this be the raw material for the cattle of the future?(Provided: Bryan Lessard / CSIRO)

Alternative routes to the market

It’s not just the new foods that consumers see coming to supermarket shelves, it’s how food is available to consumers in the first place.

On the south coast of WA, Dirty Clean Food sells regeneratively grown free-range hams as a flagship product this Christmas.

And they deliver meat direct to Western Australians in just days, without the hassle of a checkout line.

Managing Director Jay Albany said it was the pandemic that sparked the initial change in their business model, but is now here to stay.

“Our world completely changed during COVID. We looked at drop shipping and probably added 1,500 customers in six weeks,” Mr. Albany said.

“We’ve gone from 75 percent business commerce to 90 percent delivery.”

“The flagship product for this holiday season is Christmas ham.”

Two men on a farm in hot weather with pigsty in the background
Jay Albany, CEO of Dirty Clean Food, at a free range pig farm(Rural ABC; Angus mackintosh)


Source link

]]>
Why Tesla stock rose on Thursday https://regbiomed.com/why-tesla-stock-rose-on-thursday/ Thu, 23 Dec 2021 17:05:37 +0000 https://regbiomed.com/why-tesla-stock-rose-on-thursday/ What happened You’re here (NASDAQ: TSLA) the stock rose Thursday morning as Wall Street analysts competed to offer increasingly bullish forecasts for the electric carmaker’s “deliveries” in the fourth quarter. As of 11:40 a.m. ET, Tesla stock was up 3.7% from yesterday’s close. Image source: Getty Images. So what As reported by TheFly.com, yesterday analysts […]]]>

What happened

You’re here (NASDAQ: TSLA) the stock rose Thursday morning as Wall Street analysts competed to offer increasingly bullish forecasts for the electric carmaker’s “deliveries” in the fourth quarter.

As of 11:40 a.m. ET, Tesla stock was up 3.7% from yesterday’s close.

Image source: Getty Images.

So what

As reported by TheFly.com, yesterday analysts at RBC Capital predicted that when Tesla releases its sales data for the fourth quarter, it will reveal that the company sold 285,000 electric cars in the quarter, up 18% sequentially from the previous quarter and 58% year on year on the other.

If RBC were right about this, Tesla would also end up selling 8.6% more cars than even RBC initially expected, and 6.7% more than the “consensus” number of 267,000 – but that’s not the case. the best news for Tesla investors.

This morning the investment bank Swiss credit RBC rose with a prediction that Tesla’s deliveries could be even higher. According to CS, Tesla will deliver 290,000 electric cars in the fourth quarter.

Now what

And even this isn’t the best news for Tesla investors.

As my colleague Fool Daniel Sparks pointed out earlier this week, Tesla is currently only 122,428 vehicles away from meeting its self-imposed goal of delivering 750,000 electric cars by 2021. If the figures from Credit Suisse are correct, Tesla will eventually sell 155,000 cars in December. alone – hitting their internal goal in just one month, instead of the planned three.

In a final note, CS confirms Tesla CEO Elon Musk’s own observation that “Tesla has much more demand than production.” As car buyers clamor for its cars, the only thing stopping Tesla from increasing sales even more at this point is Tesla’s limited ability to produce the cars as fast as customers want to buy them.

10 stocks we prefer over Tesla
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the ten best stocks investors can buy right now … and Tesla was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* Returns of the portfolio advisor as of December 16, 2021

Rich Smith has no position in the stocks mentioned. The Motley Fool owns and recommends Tesla. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

]]>
Scientists build the first single-cell atlas of human and porcine eyes that map genes involved in eye disorders https://regbiomed.com/scientists-build-the-first-single-cell-atlas-of-human-and-porcine-eyes-that-map-genes-involved-in-eye-disorders/ Wed, 22 Dec 2021 05:09:23 +0000 https://regbiomed.com/scientists-build-the-first-single-cell-atlas-of-human-and-porcine-eyes-that-map-genes-involved-in-eye-disorders/ A group of scientists from the Institute for Molecular and Cellular Biology (IMCB) of the Agency for Science, Technology and Research (A * STAR) built the world’s first single-cell atlas of human and porcine eyes. According to a press release, this allowed the research team to create a disease map of genes involved in eye […]]]>

A group of scientists from the Institute for Molecular and Cellular Biology (IMCB) of the Agency for Science, Technology and Research (A * STAR) built the world’s first single-cell atlas of human and porcine eyes.

According to a press release, this allowed the research team to create a disease map of genes involved in eye disorders across different cell types, as well as the key switches that control the cellular specialization of eye tissue. individual.

The work would help provide new information on human eye disease and age-related eye disorders, and could potentially pave the way for regenerative medicine and cell replacement therapies for eye disease.1

The research team, led by IMCB, consisted of researchers from the National University of Singapore (NUS), Nanyang Technological University (NTU), Singapore Eye Research Institute (SERI), Mayo Clinic, from the Icahn School of Medicine at Mount Sinai, University of Melbourne. , and the Shenzhen Eye Hospital.

The human eye is made up of different types of cells from different developmental origins and different functional roles. In order to decipher this diversity of cellular functions using single-cell RNA sequencing, the research team cataloged more than 50,000 cells in human and porcine eyes and developed a cellular atlas of these eyes that distinguishes cells. individual by the activity of their genes.

Since some eye disorders are associated with mutations in human genes, the atlas that profiles pathogenic genes in all cell types in the eye could help understand how cell types are affected by these disorders. . A map of cell surface proteins that can act as viral entry receptors in the human eye could shed light on how infections could be spread through the eye. Research has shown that ACE2 and TMPRSS2, the main cell surface proteins responsible for the entry of SARS-CoV-2 in humans, are expressed in the conjunctival cells of the eye. Similar observations have been reported by different research groups, suggesting that eye infection is likely.

“It is fascinating to observe the crosstalk of eye cells through the interaction of signaling molecules with receptors. This will help us understand how an individual cell responds to external factors such as injury, ”said Mr. Pradeep Gautam, IMCB doctoral student, A * STAR, who is the co-first author of the article.

Eye diseases such as glaucoma, which is the leading cause of blindness worldwide, is caused by the degeneration of retinal ganglion cells (RGCs). Using embryonic stem cells as a platform for differentiation, the research team generated RGC progenitor cells in culture and validated that a KLF7 switch could accelerate the generation of RGCs, opening up opportunities for the cultivation of RGCs. cultured in the laboratory to replace damaged RGCs as a potential therapy.

“This study paves the way for the creation of mature retinal ganglion cells in the laboratory, which could be exploited for the development of new approaches to reverse vision loss resulting from optic nerve degeneration, including glaucoma,” said the Dr Jonathan Loh Yuin-Han, A * STAR IMCB Director Researcher and Study Principal Investigator.

In the future, the research team hopes to use RGCs for cell therapy in patients and continues their work to validate RGCs derived from KLF7 for preclinical studies. With the understanding of key molecular switches and the ability to design cell types in culture, cells grown in the laboratory are a key to therapy.

Reference

1 Pradeep Gautam, PhD, et al; “Multi-species single-cell transcriptomic analysis of ocular compartment regulons.” Nature Communications, DOI: www.nature.com/articles/s41467-021-25968-8, September 28, 2021


Source link

]]>